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Abstract
Objective—Neutrophils are involved in the inflammatory responses during atherosclerosis. 
Human neutrophil peptides (HNPs) released from activated neutrophils exert immune modulating 
properties. We hypothesized that HNPs play an important role in neutrophil-mediated 
inflammatory cardiovascular responses in atherosclerosis.
Methods and Results—We examined the role of HNPs in endothelial-leukocyte interaction, 
platelet activation, and foam cell formation in vitro and in vivo. We demonstrated that stimulation 
of human coronary artery endothelial cells with clinically relevant concentrations of HNPs 
resulted in monocyte adhesion and transmigration; induction of oxidative stress in human 
macrophages, which accelerates foam cell formation; and activation and aggregation of human 
platelets. The administration of superoxide dismutase or anti-CD36 antibody reduced foam cell 
formation and cholesterol efflux. Mice deficient in double genes of low-density lipoprotein 
receptor and low-density lipoprotein receptor–related protein (LRP), and mice deficient in a single 
gene of LRP8, the only LRP phenotype expressed in platelets, showed reduced leukocyte rolling 
and decreased platelet aggregation and thrombus formation in response to HNP stimulation.
Conclusion—HNPs exert proatherosclerotic properties that appear to be mediated through LRP8 
signaling pathways, suggesting an important role for HNPs in the development of inflammatory 
cardiovascular diseases.
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Recent studies have revealed that polymorphonuclear neutrophils (PMNs) participate in the 
development of atherosclerotic lesions.1–5 Indeed, PMNs can be detected in human tissue 
specimens at sites of plaque rupture and erosion or in thrombi from patients with acute 
coronary syndrome.6 The number of PMNs in blood and the levels of elastase and 
myeloperoxidase (MPO) released from PMNs have been reported to be associated with 
atherosclerosis.6–8 A study in more than 350 000 patients with atherosclerosis demonstrated 
that the subjects with higher leukocyte counts have higher relative and absolute acute and 
chronic mortality rates than those with lower leukocyte counts.9 A positive correlation 
between peripheral PMN count and myocardial infarction has also been reported.10,11 In 
patients with chronic stable angina, PMN count and activation are an independent predictor 
of the presence of multiple complex stenoses irrespective of the extent of coronary artery 
disease.7,12 A recent study demonstrated that peripheral blood PMN counts are higher in 
patients with rheumatoid arthritis implicated with premature atherosclerosis than in control 
subjects.13 The increased PMN count is associated with high concentration of inflammatory 
mediators, including interleukin-6, intercellular adhesion molecule-1 (ICAM-1), E-selectin, 
and tumor necrosis factor-α in the blood.13
Using apolipoprotein E–deficient mice with fluorescent PMNs to study specifically PMN 
presence and recruitment in atherosclerotic lesions, Rotzius et al have recently shown that a 
majority of leukocytes interacting with the endothelium on lesion shoulders are PMNs, 
suggesting a significant recruitment of these cells to the plaque.14 The functional importance 
of PMNs in the formation of the atherosclerotic plaque was demonstrated by Zernecke et al,3 
who reported that the size of murine atherosclerotic plaques has been shown to be closely 
correlated with the number of PMNs in the peripheral blood, and depletion of circulating 
PMNs resulted in reduction of plaque formation.
Evidence has shown that several members of PMN-specific proteins, including human 
neutrophil peptides (HNPs) and azurocidin (heparin-binding protein) are found at the 
luminal site of the endothelium,15 suggesting their deposition by PMNs. During 
inflammation, large amounts of intracellular proteins are released from the activated PMNs 
into the extracellular milieu as a consequence of PMN degranulation, leakage during 
phagosome formation, and cell death. The highly homologous HNP-1, -2, and -3, also 
known as α-defensins, make up more than 50% of the total protein content within the 
azurophilic granules of PMNs.16 HNPs have the capacity to kill a wide spectrum of Gram-
positive and Gram-negative bacteria, fungi, and some enveloped viruses in vitro.17 Recent 
studies have demonstrated that other leukocytes, including monocytes, macrophages, T cells, 
and immature dendritic cells, also express HNPs in particular when stimulated with 
cytokines.18–20 Therefore HNPs appear to participate in both innate and acquired immunity.
In healthy volunteers, plasma levels of HNPs range from undetectable to 50 to 100 ng/mL. 
However, mean HNP levels are 2- to 4-fold greater at the onset of bacterial infection and 
during nonbacterial infection compared with healthy volunteers.21 Under septic conditions, 
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plasma HNP levels range from 900 to 170 000 ng/mL, compared with a mean of 42±53 
ng/mL in healthy controls.22 An excellent correlation exists between the concentration of 
HNPs and the number of PMNs in the blood of patients with inflammatory diseases.21 We 
speculate that these proteins released from PMNs and other leukocytes are not bystanders 
but play an active role in the development of atherosclerosis.
Indeed, HNPs are found in the luminal site of human atherosclerotic coronary arteries in 
both large- and small-vessel endothelium.23 HNPs are also found in intimal smooth muscle 
cells of atherosclerotic human cerebral arteries.24 Moreover, a significant correlation is 
observed in men between the amount of HNP deposition in skin and severity of coronary 
artery disease.25 HNP stimulation increased adhesion of the cultured human endothelial 
ECV-304 cells in plastic plate coated with gelatin.26 In porcine coronary artery, 
endothelium-dependent relaxation in response to bradykinin was significantly reduced after 
treatment with HNPs associated with an increased production of superoxide anion and a 
decreased expression of endothelial nitric oxide synthase at both levels of mRNA and 
protein.27 We observed that stimulation of human umbilical vein endothelial cells (HU-
VECs) with HNPs resulted in enhanced formation of peroxinitrite that led to endothelin-1 
production, which was largely attenuated by the treatment with the reactive oxygen species 
scavenger N-acetyl-L-cysteine.28 This observation is of interest because endothelin-1 has 
been found at increased levels in endothelial cells, smooth muscle cells, and macrophages 
within atherosclerotic plaques.25
Retention of lipoproteins within the vasculature is an important event in the pathogenesis of 
atherosclerosis. HNPs have been reported to form stable multivalent complexes with 
lipoprotein(a).29 Whereas HNPs and lipoprotein(a) individually can readily traverse through 
the endothelial cell membranes, HNP/lipoprotein(a) complexes are lodged onto the cell 
surface of endothelial and smooth muscle cells, resulting in a marked increase in the total 
amount of cell-associated lipoprotein.30 Furthermore, HNPs can stimulate the binding 
of 125I-low-density lipoprotein (LDL) to cultured HUVECs, smooth muscle cells, and 
fibroblasts in a dose-dependent and saturated manner.30 An antibody against the LDL 
receptor (LDLR) is able to inhibit the binding of 125I-HNPs to HUVECs.30 Moreover, HNPs 
bind directly to isolated α2-macroglobulin receptor (LDLR–related protein [LRP]) in a 
dose-dependent manner, and the binding is inhibited by anti-LRP antibodies and LDLR-
associated protein31 to prevent binding of LRP ligands.
Given its biological nature as an inflammatory marker, the ability to promote cellular 
oxidation, and the interacting capacity with lipoproteins described above, we hypothesized 
that HNPs function as an effector in the pathogenesis of cardiovascular diseases. 
Specifically, HNPs increase monocyte-endothelial cell interaction, accelerate foam cell 
formation, and trigger the activation of platelets through LRP receptors. This hypothesis was 
tested in vitro with cultured primary human coronary endothelial cells, human acute 
monocytic leukemia cell line (THP-1)-derived macrophages, and human primary platelets, 
and in vivo with mice with LDLR and LRP double-gene or LRP8 single-gene deficiency, 
respectively.
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The study protocol was approved by the institutional Research Ethics Board for isolation of 
HNPs from sputum of patients with cystic fibrosis and for human monocyte and platelet 
isolation from healthy nonsmoking blood donors. The animal experiments were approved by 
the institutional Animal Care and Use Committee.
HNP Isolation
HNPs were purified from pooled sputum of patients with cystic fibrosis as previously 
described32 (see supplemental material, available online at http://atvb.ahajournals.org).
Cell Activation, Adhesion, and Transmigration Assays
Primary human coronary artery endothelial cells (HCAECs) (Cell Applications, San Diego, 
CA) were used within 4 passages. Expression of CD11b was measured to evaluate human 
monocyte activation after HNP stimulation, and monocyte adhesion and transmigration 
assays were performed as previously described33 (see supplemental material).
THP-1-Derived Macrophages Expressing CD36 and CD68
The expression of surface markers CD36 and CD68 was used to identify THP-1 monocyte-
derived macrophages.34 Briefly, THP-1 cells were stimulated with 5 ng/mL phorbol 12-
myristate 13-acetate (Sigma-Aldrich) for 72 hours, and adherent cells were cultured for 
additional 24 hours. The cells were then incubated with mouse anti-human CD36- 
(Invitrogen, Carlsbad, CA) or CD68-FITC antibody (AbD Serotec, Oxford, United 
Kingdom) for 30 minutes followed by flow cytometric analysis (FACSCanto flow cytometer, 
Becton Dickinson, Franklin Lakes, NJ).
Foam Cell Assay
The macrophages described above were incubated with 10 μg/mL HNPs, 50 μg/mL native 
LDL (Calbiochem, La Jolla, CA), or HNPs and LDL together in serum-free medium for 16 
hours. As for the positive control condition, macrophages were incubated with 50 μg/mL 
oxidized LDL (oxLDL) (Kalen Biomedical, Savage, MD) or in combination with HNPs for 
16 hours. To investigate the effects of HNPs on LDL oxidation in macrophages, additional 
cells were treated with the O2− scavenger superoxide dismutase (200 U/mL, Sigma-Aldrich) 
5 minutes before the incubation with HNPs and LDL. The foam cell formation was 
evaluated as previously described.35
Cholesterol Efflux Assay
To label the intracellular cholesterol pool, the THP-1 monocyte-derived macrophages were 
loaded with HNPs, LDL, oxLDL, anti-CD36 antibody and fluorescent Pennsylvania 
Green/N-alkyl-3β-cholesterylamine-derived molecular probe (F-Ch, 10 μmol/L from a 10 
mmol/L dimethyl sulfoxide stock solution, provided by Dr B. Peterson, University of 
Kansas). After 24 hours, cells were washed and incubated in 1% FBS medium for another 
12 hours to allow the labeled cholesterol to be distributed to various intracellular 
compartments. After washing, efflux was induced by addition of high-density lipoprotein 
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(100 μg/mL) for 1 hour. The medium was collected, and cells were lysed and centrifuged at 
13 200g for 10 minutes. The F-Ch in the medium and cell lysates was quantified relative to 
individual standard curves using excitation and emission wavelengths of 485 and 535 nm, 
respectively.36
Murine Platelet Isolation
Male B6129SF2-Lrp8tm1Her/J mice (6 to 8 weeks, Jackson Laboratory, Bar Harbor, ME) 
and heterozygotes were mated to generate LRP8+/+ and LRP8−/− littermates. LRP8−/− mice 
have 2 exons deleted from the cytoplasmic domain of the LRP8 receptor, resulting in a DNA 
sequence that is 100 base pairs shorter than full-length gene sequence in wild-type mice. 
Platelets from mice were isolated as previously described to obtain platelet-rich plasma 
(PRP) and platelet-poor plasma.37 Gel filtration of PRP on columns of Sepharose 2B was 
performed, and 2×108/mL of platelets was used in experiments.
Competitive Binding Assay Between HNPs and Recombinant Human LRP8
HNPs were preincubated with recombinant human LRP8 (R&D Systems Inc, Minneapolis, 
MN) at a 10:1 molar ratio for 30 minutes at 37°C. Murine and human platelets were 
stimulated at room temperature for 5 minutes with HNPs (10 μg/mL), vehicle, or the mixture 
of HNPs and recombinant human LRP8. Platelets were stained with anti-mouse CD62P-
FITC antibody (BD Biosciences, Mississauga, ON) or anti-human CD62P-FITC antibody 
(R&D Systems), respectively, for 25 minutes and fixed for analysis by flow cytometry.
Platelet Aggregation Assay
Human and murine gel-filtered platelets and PRP were stimulated with HNPs, and 
aggregation was assessed at 37°C using an aggregometer. For priming experiments, murine 
and human PRP were incubated with HNPs or vehicle for 2 minutes before the addition of 
ADP. At the end of the aggregation experiment, an aliquot of 30 μL of PRP from each 
condition was placed on coverslips for examination of thrombus formation under a confocal 
microscope.
Murine Pulmonary Endothelial Cell Isolation
Male LRP8−/− and age (2 to 3 weeks) and background strain-matched mice (Jackson 
Laboratory) were used for endothelial cell isolation by using rat anti-mouse CD31 antibody 
(PECAM-1, Bio-legend, San Diego, CA) followed by a magnetic separation (Dynal MPC-S, 
Invitrogen Dynal AS, Oslo, Norway) (see supplemental material for details). FITC rat anti-
mouse CD54/ICAM-1 monoclonal antibody (1:50, Biolegend), PE rat anti-mouse CD106/
vascular cell adhesion molecule-1 monoclonal antibody (1:50, GenWay Biotech, Inc, San 
Diego, CA), and DAPI (Molecular Probe, Molecular Probes, Inc, Eugene, OR) were used for 
immunostaining, followed by quantitative analysis using ImageJ software (NIH, http://
imagej.nih.gov/ij/download.html).
Mouse Monocyte Isolation and Flow Cytometry
Male LRP8−/− and age (2 to 3 weeks) and background strain-matched mice (Jackson 
Laboratory) were euthanized by overdose anesthesia for monocyte isolation from bone 
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marrow (Mouse Monocyte Enrichment Kit, Stemcell Technologies Inc, Vancouver, British 
Columbia, Canada). Monocytes (2×105) were suspended in RPMI-1640 in 24-well plates for 
2 hours and then incubated without or with HNPs 10 μg/mL for 1 hour. The cells were 
stained with unlabeled or PE rat anti-mouse CD11b monoclonal antibody (Biolegend) for 30 
minutes at room temperature and then were analyzed using a BD FACSCanto with BD 
FACSDiva software (BD Biosciences, Mountain View, CA).
Measurements
Concentrations of reactive nitrogen species, HNPs, MPO, chemokines, and adhesion 
molecules were measured (see supplemental material).
Intravital Microscopy
Leukocyte Adhesion—Male B6129SF2 and age-matched (6 to 8 weeks) and background 
strain–matched Ldlrtm1Her/Lrpap1tm1Her/J, and LRP8−/− mice (Jackson Laboratory) were 
anesthetized and received intravenously HNPs (10 mg/kg body weight corresponding to 
approximately 10 μg/mL)38 or vehicle control solution. In additional experiments, platelets 
were depleted in mice who received intraperitoneal injection of rat anti-mouse CD41 
monoclonal antibody at 2 μg per mouse (from a 500 μg/mL PBS stock solution provided by 
Dr A. Lazarus, the University of Toronto) 24 hours before HNP injection. This dose and 
timing of application of anti-CD41 resulted in 80% platelet depletion in the whole blood. An 
equal volume of PBS was used as for vehicle control.
To label circulating leukocytes,39 rhodamine 6G at 200 μL (20 μg/μL, Sigma-Aldrich, St. 
Louis, MO) was injected intravenously. The carotid artery was exposed and monitored under 
an upright microscope (Axiotechvario 100HD, Zeiss, Jena, Germany) on a custom-built, 
computer-controlled warmed stage. The percentage of rolling leukocytes was calculated as 
previously described.39
Platelet Aggregation—Male LRP8−/− and age (6 to 8 weeks) and background strain-
matched mice (Jackson Laboratory) were anesthetized and received intravenously HNPs (10 
mg/kg body weight)38 or vehicle control solution. Ex vivo–labeled platelets (250×106 to 
300×106) were infused intravenously into the tail vein for real-time visualization by using 
the intravital fluorescence microscope setup described above. The thrombus formation was 
recorded during the first 15 minutes after FeCl3 administration to determine the time 
required for reaching maximal vessel occlusion.
Statistical Analysis
Data are presented as a means±SE. Statistical significance was determined using a 1-way 
ANOVA followed by a Dunnett comparison. Analyses were performed using GraphPad 
Prism, version 5.00c (GraphPad Software Inc, San Diego, CA). A probability value <0.05 
was considered statistically significant.
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HNPs Induce Monocyte-Endothelial Interaction and Chemokine Production
When the HCAECs were incubated with HNPs, monocyte adhesion to HCAECs increased at 
10 μg/mL compared with the vehicle control group (Figure 1A). In addition, HNPs induced 
significant monocyte transmigration through the HCAEC monolayer in a dose-dependent 
manner (Figure 1B). The expression of ICAM-1 but not vascular cell adhesion molecule-1 
increased in HCAECs, and CD11b increased in human monocytes after stimulation with 
HNPs, compared with the vehicle control groups (Figure 1C and 1D). An increase in the 
production of interleukin-8 was observed in the cultural supernatants of both HCAECs and 
monocytes after HNP stimulation at 10 μg/mL (Figure 1E) and monocyte chemotactic 
protein-1 in HCAECs at both 1 μg/mL and 10 μg/mL (Figure 1F).
HNPs Increase Oxidative Stress and Accelerate Foam Cell Formation
The macrophage scavenger receptors CD36 and CD68 are major receptors responsible for 
uptake of modified LDL contributing to foam cell formation. We observed an increase in 
macrophage surface expression of CD36 and CD68 after stimulation with HNPs, as 
compared with the vehicle control group (Figure 2A and 2B). An enhanced oxidative stress 
as reflected by nitrotyrosine formation was observed in macrophages after HNP stimulation 
at 10 μg/mL (Figure 2C).
Incubation of macrophages with oxLDL resulted in increased Oil Red O staining, indicative 
of foam cell formation (Figure 2D and 2E). A combined stimulation of oxLDL and HNPs 
did not result in any further increase in Oil Red O staining. A similar increase in intracellular 
Oil Red O staining as seen with oxLDL incubation was observed after macrophages were 
incubated together with LDL and HNPs but not with HNP vehicle control buffer (Figure 2D 
and 2E). The HNP-induced foam cell formation (Figure 2D and 2E) and cholesterol efflux 
(Figure 2F) were largely attenuated by the treatment with superoxide dismutase and anti-
CD36 blocking antibody, respectively.
HNPs Activate Platelets
Incubation of platelets with HNPs induced a dose-dependent increase in CD62P expression 
in human PRP (Figure 3A). Similar results were seen in murine PRP (Figure 3B). The HNP-
induced platelet activation was associated with an increase in aggregation in human platelets 
(Figure 3C), but not in murine platelets (data not shown). The HNP-induced human platelet 
aggregation resulted in thrombus formation detected in culture supernatants (Figure 3D).
We then examined whether HNPs sensitize the weak agonist ADP for platelet aggregation. 
When human and murine platelets were primed with HNPs or vehicle control followed 2 
minutes later by incubation with ADP (1.25 μmol/L for human, 5 μmol/L for murine cells), a 
significantly prolonged aggregation was observed in both human (Figure 3E) and murine 
(Figure 3G) platelets as compared with a transient aggregation after ADP stimulation alone. 
The increased platelet aggregation by HNP priming was associated with greater thrombus 
formation as compared with ADP alone (Figure 3F and 3H).
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HNPs Mediate Cellular Inflammatory Responses Through LRP Signaling
To understand the signaling mechanisms by which HNPs induced cell adhesion, we repeated 
the leukocyte adhesion experiments in wild-type and the LDLR and LRP double-gene 
knockout mice by using an intravital microscopy setup. We observed a dramatic increase in 
leukocyte rolling in carotid artery 4 hours after HNP challenge in wild-type control mice 
(Figure 4A and 4B). In contrast, there was a significant decrease in leukocyte rolling in the 
LDLR−/−/LRP−/− mice (Figure 4C) despite the observation that the plasma level of HNPs 
and MPO activity were identical in both the wild-type and the gene knockout mice (Figure 
4D and 4E). These results suggest a role of LRP signaling in mediating the HNP-induced 
leukocyte adhesion in vivo.
To identify the specific phenotype of LRP in mediating the HNP-induced inflammation, we 
went further, to examine the role of LRP8 in leukocyte rolling and platelet activation, 
because LRP8 is the only LRP family member expressed on platelets.40 We first observed a 
significant decrease in leukocyte rolling in the LRP8−/− mice as compared with the wild-
type mice (Figure 4C) given that the plasma level of HNPs and MPO activity were identical 
in both the wild-type and the gene knockout mice (Figure 4D and 4E).
We then conducted a competitive binding assay in which recombinant human LRP8 was 
incubated with HNPs at a 1:10 molar ratio 30 minutes before stimulation of human platelets. 
HNPs alone induced an increase in CD62P expression that was dramatically reduced in the 
presence of recombinant human LRP8 (Figure 5A). We observed a decrease in CD62P 
expression in platelets isolated from LRP8−/− mice after HNP stimulation as compared with 
the wild-type mice, whereas stimulation with thrombin (5 U/mL) resulted in a similar 
increase in CD62P expression in both groups (Figure 5B). This phenomenon suggests a 
specific role for LRP8 in mediating the HNP-induced platelet activation.
Under in vivo conditions in which mice received intravenous injection of HNPs, the platelet 
intensity/area representing platelet aggregation was significantly greater in the wild-type 
mice but remained low in the LRP8−/− mice (Figure 5C and 5D). The time to reach maximal 
occlusion of carotid artery prolonged significantly in the LRP8−/− mice compared with the 
wild-type mice (Figure 5E).
To verify whether endothelial, monocytic, or platelet LRP8 is required for increased 
monocyte adhesion in vivo, we examined leukocyte rolling under intravital microscope in 
the presence and absence of platelets after HNP stimulation in LRP8−/− mice. Our results 
show that the absence of platelets slightly reduced leukocyte rolling in the wild-type mice, 
whereas platelet LRP8 is not required for leukocyte adhesion (Figure 5F).
To examine the exact role of endothelial and monocytic LRP8 in contributing to leukocyte 
rolling, we went further, to measure cell surface markers of activation in vitro endothelial 
cells and monocytes isolated from wild-type and LRP8−/− mice. We demonstrated that the 
expression of vascular cell adhesion molecule-1 and ICAM-1 by endothelial cells decreased 
(Figure 5G), whereas CD11b expression was not significantly altered (Figure 5H) in the 
absence of LRP8 after HNP stimulation.
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Several recent advances have suggested that PMNs play a functional role in atherosclerotic 
progression. By using a small-molecule antagonist to increase peripheral PMNs, Zernecke et 
al demonstrated a close correlation between murine PMN counts and atherosclerotic lesion 
size.3 Furthermore, depletion of PMNs significantly reduced plaque formation, confirming a 
role for PMNs in their formation.3,41 Rotzius et al have shown substantial numbers of PMNs 
in aortic plaques, especially in the shoulder regions.14
One of the criticisms against the involvement of PMNs in atherosclerosis has been their lack 
of direct detection within lesions in human atherosclerosis. It has been suggested that the 
short life span and high turnover of emigrated PMNs coupled with technical limitations in 
accurately identifying them could account for this discrepancy. Hence, even low numbers of 
plaque PMNs may represent significant recruitment of cells that have undergone decay, 
leaving behind only “footprints” revealing their presence. Indeed, it has been shown that the 
abundant content of HNPs released from activated PMNs are located in luminal site of 
human atherosclerotic coronary arteries23 and around intimal and medial smooth muscle 
cells within human atherosclerotic carotid and coronary arteries.20,23 HNPs were found in 
lesions in which intimal thickening was minimal, suggesting that HNP deposition occurs 
early in the disease process.20,23 Furthermore, a significant correlation was revealed between 
HNP skin deposition and the severity of coronary artery diseases, as evaluated by the 
number of blood vessels associated with focal lesions and stenosis.25
We demonstrated that HNPs may act not only as a biomarker like MPO to predict coronary 
diseases, as previously reported,42 but also function as an effector to induce or deteriorate 
inflammatory cardiac events by inducing endothelium-monocyte interaction through 
increasing the conventional receptor-ligand interaction between ICAM-1 and CD11b, 
oxidative stress and foam cell formation. In a previous study, we also showed that the 
stimulation of HUVECs with HNPs dose-dependently increases COX-2 expression.28 The 
latter is required for integrin-dependent endothelial cell activation and migration.43
On adhesion to the endothelial wall, the monocytes being recruited to the lesion-prone sites 
play a critical role in the development of atherosclerosis. This process is governed by 
inflammatory molecules, such as monocyte chemotactic protein-1, endothelin-1, and 
interleukin-8.44 We demonstrate that HNPs can activate endothelial cells to increase the 
production of monocyte chemotactic protein-1, a powerful inducer of monocyte chemotaxis. 
The presence of monocyte chemotactic protein-1 is likely responsible for potentiating 
monocyte chemotaxis through the endothelium in our in vitro assays. However, there may be 
other mechanisms contributing to the observed monocyte chemotaxis. We have previously 
shown in primary human endothelial cells that HNPs increase the production of 
endothelin-1, another known monocyte chemoattractant,28 and induce the expression of 
leukocyte function-associated antigen-1 in lymphocytes.33 Besides the chemoattractive 
properties of HNPs through secondary production of chemokines, HNPs have also 
demonstrated direct chemotactic activity toward monocytes and dendritic cells at nanomolar 
concentrations.45
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Once trapped in the arterial wall, monocytes can undergo phenotypic differentiation into 
macrophages and contribute to atherosclerosis-associated inflammation through formation of 
foam cells. The oxidation of LDL by reactive oxygen species is a well-known mechanism of 
the formation of foam cells, a characteristic feature of atherosclerosis at all stages of disease 
progression. We and others have previously demonstrated the production of reactive oxygen 
species and reactive nitrogen species, including superoxide anion, H2O2, and 
nitrotyrosine,27,28 on HNP stimulation in endothelial and epithelial cells. In the present 
study, we observed a significant production of nitrotyrosine, reflecting peroxynitrite 
formation when macrophages are stimulated with HNPs. Nitrotyrosine is a known molecule 
contributing to the oxidation of LDL and thus is likely to contribute to increased foam cell 
formation in the presence of HNPs. This concept is further supported by the observation that 
the use of the reactive oxygen species scavenger superoxide dismutase significantly 
decreases the foam cell formation. In addition, macrophage scavenger receptors CD36 and 
CD68 are the major receptors for macrophages to internalize oxLDL to become lipid 
engorged foam cells. Our results suggest that the HNP-induced increase in the surface 
expression of CD36 has contributed to the further enhancement in foam cell formation.
Platelets play a central role in physiological hemostasis but also contribute to 
atherothrombosis in pathological conditions. We have identified the ability of HNPs to dose-
dependently enhance CD62P expression on human and murine platelets. CD62 is not only a 
marker of platelet α-degranulation but also is responsible for mediating various 
inflammatory responses through interactions with P-selectin glycoprotein ligand-1 on 
monocytes and endothelial cells.46 Furthermore, CD62P is elevated in patients with acute 
coronary syndrome47 and has been found to promote atherosclerosis in apolipoprotein E−/− 
mouse models.48 The functional consequence of HNP-mediated platelet activation is 
demonstrated by the ability of HNPs to independently induce human platelet aggregation 
and sensitize both murine and human aggregation in response to ADP. The relatively modest 
response in human platelets, compared with murine platelets, in response to HNP 
stimulation may be donor specific, and a larger cohort of carefully screened subjects may be 
required to define maximal response.
We examined the role of LRP in initiating the HNP-induced cell-cell interaction for several 
reasons: (1) LRP has been shown to regulate integrin CD11b/CD18-mediated adhesion 
between monocytes and the endothelium49; (2) inhibition of LRP decreases leukocyte 
pulmonary infiltration and the acid-induced lung injury in a mouse model overexpressing 
HNPs50; (3) HNPs have been reported to bind to LRP, resulting in HNP internalization by 
smooth muscle cells31; and (4) the HNP-induced inhibition of aortic contractility was 
abolished by the use of anti-LRP antibodies and the LRP antagonist receptor-associated 
protein.31 Furthermore, HNPs and LDL formed stable complexes in solution and on the 
endothelial cell surface,30 the interaction between HNPs and LDL resulted in LDL retention 
and slowed LDL degradation in endothelium,24,30 and anti-LDLR antibodies that block LDL 
binding inhibited the binding of HNPs to HUVECs.30 We thus chose the LRP and LDLR 
double-gene knockout mice to keep the potential binding background as clean as possible. 
Our results suggest that LRP is required for HNP signaling by demonstrating a reduced 
leukocyte flux after HNP stimulation in LRP−/−/LDLR−/− mice and decreased foam cell 
formation in the macrophages isolated from LRP−/−/LDLR−/− mice. This observation 
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suggests that the LRP family plays an important role in the HNP-induced inflammatory 
events.
LRP is a large family consisting of several members.49 To identify the specific phenotype of 
LRP in mediating the HNP-induced inflammation, we examined the effects of HNP8 in 
leukocyte rolling and platelet activation because only LRP8 is expressed in platelets.40 
HNPs alone induce an increase in CD62P expression that was dramatically reduced in the 
presence of recombinant human LRP8, indicating competitive inhibitory effects between the 
recombinant human LRP8 and HNPs in platelet activation. Our results also suggest that the 
HNP-induced platelet activation is independent of the thrombin pathway. The requirement of 
LRP8 signaling in mediating the HNP-induced inflammatory responses is further supported 
by using LRP8−/− mice, where reduced leukocyte rolling, platelet activation, and thrombus 
formation are seen after stimulation with HNPs. The endothelial but not monocyte LRP8 
appears to play a major role in mediating the HNP-induced cell-cell interaction, which is 
supported by our in vitro data following direct stimulation of HNPs on these cell types 
isolated from wild-type and LRP8−/− mice. Interestingly, our data also suggest that platelet 
LRP8 is not required for leukocyte adhesion, although platelets have been reported to 
contribute to leukocyte rolling.51,52
It is noteworthy that LRP8−/− mice do not experience hypercholesterolemia as LDLR 
knockout mice do53; thus, the HNP-induced platelet activation is likely independent of 
modification of lipid metabolism, although this issue is not addressed in the present study. 
Furthermore, LRP8−/− mice have been shown to have decreased platelet activation and 
prolonged carotid artery occlusion time in response to ADP and thrombin stimulation, 
compared with littermate controls.54 Our study examining platelet responses to HNPs in 
LRP8−/− may provide novel ligand-membrane protein interaction in addition to conventional 
ADP and thrombin pathways.
In summary, HNPs can initiate the interaction between the endothelium and monocytes, 
induce leukocyte transendothelial migration, and increase foam cell formation and platelet 
activation and aggregation through LRP8 signaling pathways. The role of HNPs in the 
pathogenesis of inflammatory cardiovascular diseases warrants further investigation to 
confirm their potential as a therapeutic target.
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Human neutrophil peptides (HNPs) induce leukocyte-monocyte interaction. A, Human 
monocyte adhesion on human coronary artery endothelial cells (HCAECs) after stimulation 
with HNPs for 4 hours. V indicates vehicle. B, Monocyte (defined by CD33 as surface 
marker) transmigration through HCAECs after stimulation with HNPs. C, Expression of 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) in HCAECs after stimulation with HNPs for 4 hours. D, CD11 expression 1 hour 
after HNP stimulation in primary human monocytes. E, Interleukin-8 (IL-8) production in 
coculture supernatants of HCAECs and monocytes stimulated with HNPs for 4 hours (n=5 
experiments). F, Monocyte chemotactic protein-1 (MCP-1) production in HCAECs 
stimulated with HNPs for 4 hours (n=5 experiments). *P<0.05 vs V under identical 
conditions.
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Human neutrophil peptides (HNPs) increase oxidative stress and foam cell formation. A and 
B, Surface expression of CD36 and CD68 on human acute monocytic leukemia cell line 
(THP-1) derived macrophages stimulated with HNPs or vehicle (V) control for 8 hours. C, 
Concentration of nitrotyrosine measured in human THP-1 derived macrophage lysates after 
HNP stimulation. n=5 experiments. D, Foam cell formation, quantified by Oil Red O (ORO) 
staining. Human macrophages were incubated with HNPs (10 μg/mL) in the presence of 
low-density lipoprotein (LDL) or oxidized LDL (oxLDL) for 16 hours. In additional 
experiments, superoxide dismutase (SOD) or anti-CD36 blocking antibody was added 30 
minutes before the stimulation with HNPs. n=10 experiments. E, Representative cells with 
ORO staining in different groups described in D. F, Cholesterol efflux. ‡P<0.05 vs V, 
*P<0.05 vs LDL alone, †P<0.05 vs the LDL+HNP group.
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Human neutrophil peptides (HNPs) induce platelet activation. A and B, Surface expression 
of CD62P in human and murine platelet-rich plasma (PRP) stimulated with either HNPs (1, 
10 μg/mL), vehicle control (V), or human α-thrombin (Thr) (5 U/mL). C, Dose-dependent 
increase in platelet aggregation in human PRP after stimulation with HNPs at 10 or 100 
μg/mL. D, Thrombus formation after the HNP stimulation shown in C. E, HNP-induced 
human platelet aggregation and synergy with ADP. Human PRP was primed with HNPs (10 
μg/mL) or vehicle control followed 2 minutes later by incubation with ADP (1.25 μmol/L). 
Platelet aggregation is illustrated by representative actual traces (top) and by average traces 
(bottom, n=7 experiments). F, Thrombus formation after the HNP stimulation shown in E. G, 
HNP-induced murine platelet aggregation and synergy with ADP. Murine PRP was primed 
with HNPs (10 μg/mL) or vehicle control followed 2 minutes later by incubation with ADP 
(5 μmol/L). Platelet aggregation is illustrated by representative actual traces (top) and by 
average traces (bottom, n=7 experiments). H, Thrombus formation after the HNP stimulation 
shown in G. *P<0.05 vs V group under identical conditions.
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Human neutrophil peptides (HNPs) induce leukocyte adhesion mediated by low-density 
lipoprotein receptor (LDLR)–related protein 8 (LRP8) in vivo. A and B, Leukocyte rolling 
in carotid artery was monitored by intravital microscopy in wild-type (WT) mice 4 hours 
after receiving intravenous injection of vehicle (V) or HNPs (10 mg/kg). C, Mean values of 
leukocyte rolling in WT, LRP8−/−, or LDLR−/−/LRP−/− mice 4 hours after injection with 
HNPs. D and E, Mean plasma levels of HNPs and myeloperoxidase (MPO) activity 
measured in WT, LRP8−/−, or LDLR−/−/LRP−/− mice 4 hours after injection with HNPs. 
*P<0.05 vs V under identical conditions, †P<0.05 vs WT under identical conditions.
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Low-density lipoprotein receptor–related protein 8 (LRP8) plays a role in the human 
neutrophil peptide (HNP)–induced platelet activation and leukocyte rolling. A, Surface 
expression of CD62P in human platelet-rich plasma (PRP) after stimulation with vehicle 
control (V) or HNPs (10 μg/mL) in the presence or absence of recombinant human LRP8 
(rhLRP8) (n=7 experiments). B, Surface expression of CD62P in murine PRP isolated from 
wild-type (WT) or LRP8−/− mice after incubation with HNPs (1 or 10 μg/mL) or thrombin 
(5 U/mL) (n=7 experiments). C, Representative images of platelet aggregation under 
fluorescence intravital microscope in WT and LRP8−/− mice 4 hours after intravenous 
injection of HNPs. Low-dose FeCl3 was topically dropped on carotid artery to stimulate 
platelet aggregation. D, Mean values of fluorescent density of platelets deposited on the 
vessel wall 5 minutes after FeCl3. E, Time required reaching maximal vessel occlusion after 
FeCl3 stimulation in mice treated with HNPs. F, Platelet LRP8 is not required for increasing 
leukocyte rolling. Platelets were depleted by intraperitoneal injection of rat anti-mouse 
CD41 monoclonal antibody (2 μg per mouse) in WT and LRP8−/− mice 24 hours before 
intravenous injection of HNPs. Leukocyte rolling in carotid artery was monitored by 
intravital microscopy 4 hours after receiving HNPs. G, Expression of intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in response to HNP 
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stimulation (10 μg/mL) for 4 hours by primary endothelial cells isolated from WT and 
LRP8−/− mice (n=5). H, Expression of CD11b in response to HNP stimulation (10 μg/mL) 
for 1 hour by primary monocytes isolated from bone marrow of WT and LRP8−/− mice 
(n=5). *P<0.05 vs WT under identical conditions, †P<0.05 vs unstained, ‡P<0.05 vs stained.
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